D.E. Shaw & Co’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
D.E. Shaw & Co's NVCR Position: Q3 2026 in Review
D.E. Shaw & Co increased its NovoCure (NVCR) stake by 27% in Q3 2026, buying an estimated $4.59M and bringing the position to 1,297,565 shares worth $20.7M. The position accounts for 0.01% of the portfolio, ranked #1286.
D.E. Shaw & Co first reported a position in NVCR in Q4 2016 and has held it in 34 quarters since. The position peaked at $34.6M in Q2 2019. 242 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.
- D.E. Shaw & Co held 1,297,565 shares of NovoCure worth $20.7M as of Q3 2026.
- D.E. Shaw & Co bought 275,085 NovoCure shares in Q3 2026, an estimated $4.59M.
- NovoCure made up 0.01% of D.E. Shaw & Co's portfolio in Q3 2026, its #1286 holding.
- D.E. Shaw & Co first reported a position in NovoCure in Q4 2016 and has held it in 34 quarters since.
- D.E. Shaw & Co's NovoCure position peaked at $34.6M in Q2 2019.
- 242 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.